Omalizumab shows promise for alpha-gal syndrome patients
Preliminary findings indicate omalizumab may reduce reaction severity in alpha-gal syndrome, the tick-related red meat allergy, but researchers call for trials.
Preliminary findings indicate omalizumab may reduce reaction severity in alpha-gal syndrome, the tick-related red meat allergy, but researchers call for trials.